希腊动脉粥样硬化协会血脂异常诊断与治疗指南（2023年）执行摘要
Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.
作者信息
Katsiki N, Filippatos Td, Vlachopoulos C, Panagiotakos D, Milionis H, Tselepis A, Garoufi A, Rallidis L, Richter D, Nomikos T, Kolovou G, Kypreos K, Chrysohoou C, Tziomalos K, Skoumas I, Koutagiar I, Attilakos A, Papagianni M, Boutari C, Kotsis V, Pitsavos C, Elisaf M, Tsioufis K, Liberopoulos E
机构信息
Department of Nutritional Sciences and Dietetics, International Hellenic University, Thessaloniki, Greece.
School of Medicine, European University Cyprus, Nicosia, Cyprus.
出版信息
Atheroscler Plus. 2024 Feb 17;55:74-92. doi: 10.1016/j.athplu.2024.01.004. eCollection 2024 Mar.
Abstract
Atherosclerotic cardiovascular disease (ASCVD) remains the main cause of death worldwide, and thus its prevention, early diagnosis and treatment is of paramount importance. Dyslipidemia represents a major ASCVD risk factor that should be adequately managed at different clinical settings. 2023 guidelines of the Hellenic Atherosclerosis Society focus on the assessment of ASCVD risk, laboratory evaluation of dyslipidemias, new and emerging lipid-lowering drugs, as well as diagnosis and treatment of lipid disorders in women, the elderly and in patients with familial hypercholesterolemia, acute coronary syndromes, heart failure, stroke, chronic kidney disease, diabetes, autoimmune diseases, and non-alcoholic fatty liver disease. Statin intolerance is also discussed.
摘要
动脉粥样硬化性心血管疾病（ASCVD）仍然是全球主要的死亡原因，因此其预防、早期诊断和治疗至关重要。血脂异常是一个主要的ASCVD风险因素，在不同的临床环境中都应得到充分管理。希腊动脉粥样硬化协会2023年指南重点关注ASCVD风险评估、血脂异常的实验室评估、新型降脂药物以及女性、老年人和家族性高胆固醇血症、急性冠状动脉综合征、心力衰竭、中风、慢性肾病、糖尿病、自身免疫性疾病和非酒精性脂肪性肝病患者的脂质紊乱的诊断和治疗。还讨论了他汀类药物不耐受情况。
相似文献
1
Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023.希腊动脉粥样硬化协会血脂异常诊断与治疗指南（2023年）执行摘要
Atheroscler Plus. 2024 Feb 17;55:74-92. doi: 10.1016/j.athplu.2024.01.004. eCollection 2024 Mar.
2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.美国临床内分泌医师协会和美国内分泌学会血脂异常管理与心血管疾病预防指南
Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL.
3
Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.血管护理质量评估：临床医生对动脉粥样硬化性心血管疾病患者降脂治疗的依从性
Ann Vasc Surg. 2020 Nov;69:197-205. doi: 10.1016/j.avsg.2020.06.003. Epub 2020 Jun 15.
4
Role of Bempedoic Acid in Dyslipidemia Management.贝匹地酸在血脂异常管理中的作用。
J Cardiovasc Pharmacol. 2020 Oct;76(4):376-388. doi: 10.1097/FJC.0000000000000887.
5
Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.贝匹地酸治疗血脂异常和他汀不耐受患者。
Cardiovasc Drugs Ther. 2021 Aug;35(4):841-852. doi: 10.1007/s10557-020-07139-x. Epub 2021 Jan 27.
6
2017 Taiwan lipid guidelines for high risk patients.2017年台湾高危患者血脂指南。
J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24.
7
Umbrella Review on Non-Statin Lipid-Lowering Therapy.伞式评价：非他汀类降脂治疗。
J Cardiovasc Pharmacol Ther. 2021 Sep;26(5):437-452. doi: 10.1177/10742484211002943. Epub 2021 Apr 9.
8
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.2017 年对 2016 年美国心脏病学会专家共识决策途径的重点更新：非他汀类药物在降低动脉粥样硬化性心血管疾病风险管理中的作用：美国心脏病学会专家组的专家共识决策途径报告。
J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5.
9
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018 年美国心脏协会/美国心脏病学会/美国心血管血管外科学会/美国医师协会/美国心脏病学学院/美国糖尿病协会/美国老年学会/美国药学会/美国物理治疗协会/北美介入放射学会/国家脂质协会/美国预防、检测、评估与治疗高血压全国联合委员会临床实践指南：管理血胆固醇的系统评价。
J Am Coll Cardiol. 2019 Jun 25;73(24):3210-3227. doi: 10.1016/j.jacc.2018.11.004. Epub 2018 Nov 10.
10
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.载脂蛋白 B 代谢途径抑制剂治疗杂合子型家族性高胆固醇血症或动脉粥样硬化性心血管疾病患者的成本效果分析。
JAMA. 2016 Aug 16;316(7):743-53. doi: 10.1001/jama.2016.11004.
引用本文的文献
1
Impact of Dietary Patterns on the Lipidemic Profile and the Cardiovascular Risk in Stage 1 Hypertension: A Post Hoc Analysis of the HINTreat Trial.饮食模式对1期高血压患者血脂谱及心血管风险的影响：HINTreat试验的事后分析
Nutrients. 2025 Aug 14;17(16):2632. doi: 10.3390/nu17162632.
2
Sodium, potassium intake and urinary sodium-to-potassium ratio in rheumatoid arthritis: association with markers of cardiovascular dysfunction and disease-related parameters.类风湿关节炎中钠、钾摄入量及尿钠钾比：与心血管功能障碍标志物及疾病相关参数的关联
Clin Rheumatol. 2025 Sep;44(9):3515-3523. doi: 10.1007/s10067-025-07608-4. Epub 2025 Aug 1.
3
High-density lipoprotein cholesterol and multiple sclerosis: a systematic review and meta-analysis.高密度脂蛋白胆固醇与多发性硬化症：一项系统评价与荟萃分析
Arch Med Sci Atheroscler Dis. 2025 Jun 2;10:e69-e77. doi: 10.5114/amsad/204578. eCollection 2025.
4
Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?正在研发的Lp(a)降低药物：应对心血管疾病风险负担的新时代？
Pharmaceuticals (Basel). 2025 May 19;18(5):753. doi: 10.3390/ph18050753.
5
Circulating MicroRNAs Related to Arterial Stiffness in Adults with HIV Infection.与成人HIV感染患者动脉僵硬度相关的循环微小RNA
Viruses. 2024 Dec 19;16(12):1945. doi: 10.3390/v16121945.
6
Prevalence and Risk Factors for Atherosclerotic Cardiovascular Disease in 7704 Individuals: An Analysis from the Greek Registry for the Prevalence of Familial Hypercholesterolemia (GRegistry-FH).7704例个体动脉粥样硬化性心血管疾病的患病率及危险因素：来自希腊家族性高胆固醇血症患病率登记处（GRegistry-FH）的分析
J Cardiovasc Dev Dis. 2024 Dec 23;11(12):411. doi: 10.3390/jcdd11120411.
7
Effect of Different Dietary Patterns on Cardiometabolic Risk Factors: An Umbrella Review of Systematic Reviews and Meta-Analyses.不同饮食模式对心血管代谢危险因素的影响：系统评价和荟萃分析的伞状综述
Nutrients. 2024 Nov 13;16(22):3873. doi: 10.3390/nu16223873.
8
Residual cardiovascular disease risk in heart failure patients. What is the real role of lipid-lowering therapy?心力衰竭患者残留的心血管疾病风险。降脂治疗的实际作用是什么？
Arch Med Sci. 2024 Jul 8;20(4):1358-1362. doi: 10.5114/aoms/190351. eCollection 2024.
9
The Association between Food Groups, Nutraceuticals, and Food Supplements Consumption on Vascular Health Outcomes: A Literature Review.食物类别、营养保健品及膳食补充剂的摄入与血管健康结局之间的关联：一项文献综述
Life (Basel). 2024 Sep 23;14(9):1210. doi: 10.3390/life14091210.
本文引用的文献
1
Updates in Drug Treatment of Severe Hypertriglyceridemia.严重高甘油三酯血症的药物治疗进展。
Curr Atheroscler Rep. 2023 Oct;25(10):701-709. doi: 10.1007/s11883-023-01140-z. Epub 2023 Aug 29.
2
From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need.从非酒精性脂肪性肝病（NAFLD）到脂肪性肝病（SLD）：为这种普遍的代谢状况和未满足的临床需求完善术语的持续进程。
Metabolism. 2023 Oct;147:155664. doi: 10.1016/j.metabol.2023.155664. Epub 2023 Jul 28.
3
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.匹伐他汀预防 HIV 感染患者的心血管疾病。
N Engl J Med. 2023 Aug 24;389(8):687-699. doi: 10.1056/NEJMoa2304146. Epub 2023 Jul 23.
4
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识：新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
5
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.国际动脉粥样硬化学会家族性高胆固醇血症管理最佳实践实施指南。
Nat Rev Cardiol. 2023 Dec;20(12):845-869. doi: 10.1038/s41569-023-00892-0. Epub 2023 Jun 15.
6
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.2020年至2021年欧洲高危和极高危患者低密度脂蛋白胆固醇控制实施中的治疗差距：多国观察性圣托里尼研究
Lancet Reg Health Eur. 2023 Apr 5;29:100624. doi: 10.1016/j.lanepe.2023.100624. eCollection 2023 Jun.
7
Update on Sitosterolemia and Atherosclerosis.关于植物甾醇血症与动脉粥样硬化的最新进展
Curr Atheroscler Rep. 2023 May;25(5):181-187. doi: 10.1007/s11883-023-01092-4. Epub 2023 Mar 10.
8
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.贝匹地酸在他汀类药物不耐受患者中的心血管结局。
N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4.
9
Very low HDL levels: clinical assessment and management.极低的高密度脂蛋白水平：临床评估和管理。
Arch Endocrinol Metab. 2023 Jan 18;67(1):3-18. doi: 10.20945/2359-3997000000585.
10
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges.家族性卵磷脂：胆固醇酰基转移酶缺乏症的新治疗机会：前景与挑战。
Curr Opin Lipidol. 2023 Apr 1;34(2):35-43. doi: 10.1097/MOL.0000000000000864. Epub 2022 Dec 6.
Zotero 插件